Outcomes for the IM-treated cohort as compared with the historical cohort for all centers and for Fred Hutchinson Cancer Research Center (FHCRC) patients only
| . | All centers; OR or HR (95% CI; P)* . | FHCRC; OR or HR, (95% CI; P)* . |
|---|---|---|
| Acute GVHD | ||
| Grades 2-4 | OR = 0.67 (0.40-1.12; .13) | OR = 0.87 (0.46-1.65; .68) |
| Grades 3-4 | OR = 0.99 (0.53-1.83; .97) | OR = 0.53 (0.23-1.27; .15) |
| Extensive chronic GVHD | HR = 0.33 (0.22-0.48; < .0001) | HR = 0.65 (0.45-0.95; .03) |
| NRM | HR = 0.73 (0.44-1.20; .22) | HR = 0.49 (0.26-0.95; .03) |
| Relapse | HR = 0.56 (0.27-1.13; .10) | HR = 0.51 (0.21-1.23; .13) |
| Relapse or mortality | HR = 0.66 (0.44-1.00; .05) | HR = 0.50 (0.30-0.85; .01) |
| Mortality | HR = 0.71 (0.46-1.11; .13) | HR = 0.49 (0.28-0.87; .01) |
| Engraftment | All centers | FHCRC |
| Days to ANC > 500 | 1.5 days earlier; .009 | 1.9 days earlier; .005 |
| Days to Plts > 50 000 | 4.7 days longer; .06 | 0.6 days earlier; .77 |
| . | All centers; OR or HR (95% CI; P)* . | FHCRC; OR or HR, (95% CI; P)* . |
|---|---|---|
| Acute GVHD | ||
| Grades 2-4 | OR = 0.67 (0.40-1.12; .13) | OR = 0.87 (0.46-1.65; .68) |
| Grades 3-4 | OR = 0.99 (0.53-1.83; .97) | OR = 0.53 (0.23-1.27; .15) |
| Extensive chronic GVHD | HR = 0.33 (0.22-0.48; < .0001) | HR = 0.65 (0.45-0.95; .03) |
| NRM | HR = 0.73 (0.44-1.20; .22) | HR = 0.49 (0.26-0.95; .03) |
| Relapse | HR = 0.56 (0.27-1.13; .10) | HR = 0.51 (0.21-1.23; .13) |
| Relapse or mortality | HR = 0.66 (0.44-1.00; .05) | HR = 0.50 (0.30-0.85; .01) |
| Mortality | HR = 0.71 (0.46-1.11; .13) | HR = 0.49 (0.28-0.87; .01) |
| Engraftment | All centers | FHCRC |
| Days to ANC > 500 | 1.5 days earlier; .009 | 1.9 days earlier; .005 |
| Days to Plts > 50 000 | 4.7 days longer; .06 | 0.6 days earlier; .77 |
OR indicates odds ratio; HR, hazard ratio; NRM, nonrelapse mortality; GVHD, graft-versus-host disease; ANC, first of 3 consecutive days where the absolute neutrophil count was ≥ 500/μL; Plts, first of 7 days where the untransfused platelet count was ≥ 50 000/μL.
Ratios adjusted for EBMT score and/or stem-cell source; data reported for the IM-treated cohort relative to the historical cohort.